Eiger Pharmaceuticals Lawsuit EIGR | Deadline January 9, 2023

Eiger Pharmaceuticals Class Action Lawsuit (EIGR Lawsuit)

A lawsuit has been filed against Eiger Pharmaceuticals, (EIGR:NASDAQ) on November 8, 2022 at the court of the Northern District of California.

Investors who purchased or otherwise acquired EIGR common stock during the period from March 10, 2021 through October 4, 2022 can register their information before the deadline of January 9, 2023.

Is Eiger Pharmaceuticals Inc. Involved  in a Securities Class Action Lawsuit?

Yes, a lawsuit has been filed against Eiger Pharmaceuticals Inc. on November 8, 2022, on behalf of shareholders during the period from March 10, 2021 through October 4, 2022.

What Is The Eiger Pharmaceuticals Lawsuit About?

The Eiger Pharmaceuticals Class Action Lawsuit (NASDAQ:EIGR) (Eiger Pharmaceuticals Class Action Lawsuit) was filed on behalf of the investors who purchased Eiger Pharmaceuticals Inc. (EIGR) securities between March 10, 2021 to October 4, 2022 inclusive. For more on the EIGR Lawsuit please contact us today.

According to the Eiger Pharmaceuticals lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:

(i) Defendants overstated Eiger’s clinical and regulatory drug development expertise;

(ii) Defendants failed to properly assess, and/or ignored issues with, the design of the TOGETHER study and its ability to support the peginterferon lambda EUA;

(iii) there were issues with the conduct of the TOGETHER study and/or the TOGETHER study was not properly designed for the peginterferon lambda EUA in the current context of the pandemic;

(iv) as a result, the FDA was unlikely to approve the submission of a peginterferon lambda EUA;

(v) as a result of all the foregoing, peginterferon lambda’s regulatory and commercial prospects for the treatment of COVID-19 were overstated; and

(vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.

How much did EIGR stock drop?

Shareholders who held EIGR securities saw  stock price fell $2.51 per share, or 29.36%, to close at $6.04 per share on September 6, 2022.

Additionally, Eiger’s stock price fell $0.37 per share, or 5.01%, to close at $7.02 per share on October 5, 2022.

What does EIGR Do?

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally.

Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.

The company’s product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia.

Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Which Class Action Attorney Firm Can Help With The EIGR Lawsuit?

Levi & Korsinsky LLP is a Securities Class Action Law Firm.  For over 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Does It Cost Me To Join The EIGR Class Action?

No, there are no out of pocket costs for you to join the Eiger Pharmaceuticals Lawsuit.

What Is the Lead Plaintiff Process?

According to the Private Securities Reform Act of 1995, any investor who bought or acquired EIGR securities in the Class Period may apply for appointment as a lead plaintiff. The lead plaintiff is usually the movant who has the most financial interest in the relief sought. However, he or she must also be typical or adequate to the putative classes. The EIGR class-action lawsuit is directed by the lead plaintiff. To litigate the Eiger Pharmaceuticals Class Action Lawsuit, the lead plaintiff may choose any law firm it wishes. The ability of an investor to share in any future recovery is not tied to being the lead plaintiff in the EIGR Class Action Lawsuit.

Have other shares in other companies? Search Class Action Cases.